The GLP-1 pill developed by Hengrui Pharma and Kailera Therapeutics demonstrated encouraging efficacy but high side effect rates in two late-stage China trials. One trial targeted obesity, while the other focused on an unspecified condition. The results were reported on July 7, 2026.
According to a report published on July 7, 2026, at 11:25 AM EDT, the GLP-1 pill jointly developed by Hengrui Pharma and Kailera Therapeutics showed encouraging efficacy in two late-stage clinical trials conducted in China. One of these trials was specifically designed for the treatment of obesity. The other trial addressed a separate medical condition, though the full details of that indication were not fully available in the published snippet.
The trials represent a significant step in the clinical development of this oral GLP-1 receptor agonist. Both studies were carried out in China, highlighting the companies' focus on the Chinese market for initial late-stage testing.
The pill posted decent results in terms of efficacy, with the report characterizing them as encouraging. However, the side effect rates were high. This combination of promising therapeutic benefit alongside a notable adverse event profile is a key finding from these trials.
Specific details on the nature or severity of the side effects were not elaborated in the available text. The high rate of adverse events will likely be a focal point for regulators and the companies as they consider next steps for the drug candidate.
The GLP-1 pill is the result of a collaboration between Hengrui Pharma, a well-established Chinese pharmaceutical company, and Kailera Therapeutics, a biopharma firm. The partnership aims to bring an oral GLP-1 treatment to market.
The article was written by Elizabeth Cairns, a senior biopharma journalist who covered these trial results. The report underscores the ongoing interest in oral GLP-1 therapies as alternatives to injectable treatments for obesity and metabolic conditions.
The two late-stage China trials produced mixed results: encouraging efficacy but high side effect rates. The obesity trial is one of the indications, and the other trial's condition was not specified in the available summary. These findings were published on July 7, 2026, and were authored by Elizabeth Cairns.
Peptides referenced: GLP-1.
Related reading: Protagonist Therapeutics Provides Clinical Pipeline Update, Kailera oral GLP-1 asset hits 11% weight loss in Chinese phase 3 trials, Peptide therapy shows nerve repair in spinal cord injury clinical trial, Tampa General Hospital Sues Eli Lilly Over 340B Drug Discount Restrictions.